Verteporfin photodynamic therapy for neovascular age-related ...

40 Results (1) – study cohortTABLE 6 Baseline characteristics of eligible patients (column percentages within characteristic unless otherwise stated)Patient characteristicNumber of patients first treated> 350 days before the end of the studyNumber of patients first treated≤ 350 days before the end of the studyTotal eligible patients 4566 1655 6221(see Figure 3)GenderMale 1893 (41.5%) 689 (41.6%) 2582 (41.5%)Female 2658 (58.2%) 962 (58.1%) 3620 (58.2%)Missing 15 (0.3%) 4 (0.2%) 19 (0.3%)Age (years)Median 78 79 78Interquartile range 72–83 73–84 72–83Range 8–102 14–102 8–102Age group< 50 years 203 (4.6%) 61 (3.7%) 264 (4.2%)≥ 50 to < 65 years 345 (7.6%) 120 (7.3%) 465 (7.5%)≥ 65 to < 75 years 993 (21.7%) 319 (19.3%) 1312 (21.1%)≥ 75 to < 85 years 2180 (47.7%) 805 (48.6%) 2985 (48.0%)≥ 85 years 845 (18.5%) 350 (21.1%) 1195 (19.2%)Smoking historyUnknown 775 (17.0%) 164 (9.9%) 939 (15.1%)Current smoker 617 (13.5%) 215 (13.0%) 832 (13.4%)Ex-smoker 1543 (33.8%) 549 (33.2%) 2092 (33.6%)Never smoked 1631 (35.7%) 727 (43.9%) 2358 (37.9%)TotalThe baseline characteristics of this subset of patients and eyes are shown in Table 9, which breaksdown the data according to whether patients/eyes were classified as EFT, IFT or UNC. In the EFTgroup, predominantly classic CNV was present in 86.7% (1064/1227) and minimally classic in13.3% (163/1227). In the IFT group, predominantly classic CNV was present in 52.9% (628/1187)and minimally classic in 47.1% (559/187). The mean baseline logMAR BCVA was 50 letters(20/100) in the treated eye, which was very similar to study eyes of patients randomised in theTAP trials (53 letters). 3